The classic chicken and egg puzzle asks what came first, the chicken or the egg? We can also ask that about diets.  A so-called Western diet, though it now seems to be worldwide, has high-calorie, high-sugar and high-sodium content and has been nicknamed the 'cafeteria diet' after buffet-style restaurants, has been linked to a lifetime of health problems, dramatically increasing the risk of stroke or death at a younger age.

Researchers have determined that summers on the Norwegian archipelago of Svalbard are now warmer than at any other time in the last 1,800 years, including during medieval times when parts of the northern hemisphere were as hot as, or hotter, than today.  

They also discovered that Svalbard was not particularly cold during the recent "Little Ice Age" of the 18th and 19th centuries, when glaciers on Svalbard surged to their greatest extent in the last 10,000 years and glaciers in many parts of Western Europe also grew. They suggest that snow, rather than colder temperatures, may have fed the growth of Svalbard glaciers.

CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease. The drug candidate blocks signaling by protein Vascular Endothelial Growth Factor B (VEGF-B) and this prevents fat from accumulating in the "wrong" places, such as in muscles and in the heart. As a result, cells within these tissues are once again able to respond to insulin and blood glucose is restored to normal levels. 

The elusive 113th atomic element has been confirmed by researchers at the RIKEN Nishina Center for Accelerator-based Science (RNC). A chain of six consecutive alpha decays, produced in experiments at the RIKEN Radioisotope Beam Factory (RIBF), conclusively identifies the element through connections to well-known daughter nuclides.

That sets the stage for Japan to claim naming rights for the element, the first Asian country to name an atomic element.

According to a new market report published by Transparency Market Research, "Global Diabetes Devices Market and Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share and Forecast, 2011 - 2018," the global diabetes devices and drugs market was worth USD 50.8 billion in 2011 and is expected to reach USD 98.4 billion in 2018, growing at a CAGR of 9.9% from 2011 to 2018.

In the overall global market, North America accounted for the highest share worth USD 19.9 billion in 2011 followed by Europe. However, with the continuous population and economic growth of the Asia-Pacific region, especially India and China, it is expected to witness the highest growth rate in the next six years. 

BOTOX(R) has been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the management of urinary incontinence in adult patients with neurogenic detrusor overactivity (NDO) due to subcervical spinal cord injury (SCI) (traumatic or non-traumatic) or multiple sclerosis (MS), who are not adequately managed with anticholinergics.